Dignitana AB (DIGN) - Total Liabilities
Based on the latest financial reports, Dignitana AB (DIGN) has total liabilities worth Skr24.80 Million SEK (≈ $2.67 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dignitana AB - Total Liabilities Trend (2008–2024)
This chart illustrates how Dignitana AB's total liabilities have evolved over time, based on quarterly financial data. See Dignitana AB current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Dignitana AB Competitors by Total Liabilities
The table below lists competitors of Dignitana AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Predictive Oncology Inc
NASDAQ:POAI
|
USA | $80.57 Million |
|
Ceres Power Holdings PLC
LSE:CWR
|
UK | GBX27.85 Million |
|
Prostar Holdings Inc
V:MAPS
|
Canada | CA$844.82K |
|
MIND CTI Ltd
NASDAQ:MNDO
|
USA | $6.97 Million |
|
Asia Poly Holdings Bhd
KLSE:0105
|
Malaysia | RM77.39 Million |
|
Puncak Niaga Holdings Bhd
KLSE:6807
|
Malaysia | RM1.52 Billion |
|
N2Tech Co. Ltd
KQ:227950
|
Korea | ₩18.67 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Dignitana AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see DIGN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dignitana AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dignitana AB (2008–2024)
The table below shows the annual total liabilities of Dignitana AB from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr28.17 Million ≈ $3.03 Million |
-25.01% |
| 2023-12-31 | Skr37.57 Million ≈ $4.04 Million |
+9.52% |
| 2022-12-31 | Skr34.30 Million ≈ $3.69 Million |
-14.61% |
| 2021-12-31 | Skr40.17 Million ≈ $4.32 Million |
-33.33% |
| 2020-12-31 | Skr60.25 Million ≈ $6.48 Million |
+128.35% |
| 2019-12-31 | Skr26.39 Million ≈ $2.84 Million |
+3.85% |
| 2018-12-31 | Skr25.41 Million ≈ $2.73 Million |
-18.43% |
| 2017-12-31 | Skr31.15 Million ≈ $3.35 Million |
+291.15% |
| 2016-12-31 | Skr7.96 Million ≈ $857.05K |
+16.19% |
| 2015-12-31 | Skr6.85 Million ≈ $737.60K |
+4.74% |
| 2014-12-31 | Skr6.54 Million ≈ $704.24K |
-5.31% |
| 2013-12-31 | Skr6.91 Million ≈ $743.73K |
-5.43% |
| 2012-12-31 | Skr7.31 Million ≈ $786.46K |
+23.26% |
| 2011-12-31 | Skr5.93 Million ≈ $638.06K |
-26.42% |
| 2010-12-31 | Skr8.06 Million ≈ $867.17K |
-15.80% |
| 2009-12-31 | Skr9.57 Million ≈ $1.03 Million |
-12.26% |
| 2008-12-31 | Skr10.91 Million ≈ $1.17 Million |
-- |
About Dignitana AB
Dignitana AB (publ), a medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally. It offers DigniCap, a scalp cooling system used to reduce hair loss from chemotherapy treatments, as well as for patients receiving chemotherapy to treat other solid tumors. The company was incorporated in 2007 is headquarter… Read more